Cerebral amyloid angiopathy new risk for beta-amyloid space, says Mizuho

Science yesterday announced the death of a patient taking Biogen’s lecanemab, which is the second death discovered as one was first reported by STAT in October, Mizuho analyst Salim Syed tells investors in a research note. Both of the patients died of brain hemorrhage, the analyst points out. He says that while cerebral amyloid angiopathy "is now becoming a new risk item for the beta-amyloid space," Street models "were never fully-loaded for lecanemab." Syed points out that both patients were on at least one blood thinning agent. The analyst keeps a Buy rating on Biogen with a $325 price target.